安神胶囊对慢性精神分裂症患者认知和社会功能的影响

Impact of AnShen Capsules on Social and Cognitive Functions of the Patients Suffering from Chronic Schizophrenia

目的：探讨安神胶囊对慢性精神分裂症（Chronic Schizophrenia）患者认知和社会功能的影响。方法：采用随机、双盲、双模拟试验方法,将慢性精神分裂症患者200例随机分为安神胶囊组和维思通组,每组100例,安神胶囊组口服安神胶囊,4粒/次,3次/d;维思通组口服维思通,1~1.5 mg/d,2组均治疗8周。于治疗前和治疗8周末分别观察认知功能评定量表（WCST）、社会功能量表（SDSS）评分;于治疗前、治疗第2、4、6、8周分别观察阳性症状量表（SAPS）、阴性症状量表（SANS）、临床总体印象量表（CGI）评分,并应用药物副反应量表（TESS）评定药物的副反应。结果：治疗第8周末,2组患者SAPS、SANS及SDSS评分,均较治疗前降低,安神胶囊组SANS、SAPS评分降低较维思通组更为明显;WCST指标中除安神胶囊组患者持续应答数外均获改善,其差异有统计学意义（P〈0.01）;安神胶囊组WCST组治疗8周末SDSS各条目评分变化值比较差异均有统计学意义（P〈0.05）。安神胶囊组SANA有效率为79.9%,CGI临床进步率为86.6%;维思通组SANA有效率为85.3%,CGI临床进步率为89.3%,2组比较差异无统计学意义（P〉0.05）,安神胶囊组不良反应发生率低于维思通组。结论：安神胶囊对慢性精神分裂症患者认知和社会功能的改善更为有效。

Objective： To explore the effects of AnShen capsules on social and cognitive functions of the patients with chronic schizophrenia （CS）. Methods： By adopting randomized, double-blind and double-tummy testing method, 200 CS patients were randomized into A nShen capsules group and risperdal group, 100 cases each group, A n- Shen capsules group took AnShen capsules, four pills each time, three times per day; risperdal group risperdal, 1-1.5mg each day, both groups were treated for eight weeks. To observe Wisconsin card sorting test （WSCT） and so- cial disability screening schedule（SDSS） before treating and by the end of eighth week after treating respectively; to investigate scale for the assessment of positive symptoms （SAPS）, scale for the assessment of negative symptoms （SANS）, clinical global impression scale （CGIS） before treating, at the second, forth, sixth and eighth week after treating, to assess adverse drug reaction with Treatment Emergent Symptom Scale（TESS）. Results： By the end of the eighth week after treating, SAPS, SANS and SDSS in both groups before and after treating respectively were lower than these before treating, the decrease of A nShen capsules group was more obvious compared with risperdal group, except sustained responses, WCST indexes were improved in A rtShen capsules group, the difference had statistical meaning （P〈0.01）; the comparison of SDSS items scales between AnShen capsules group and risperdal group before treating and by the end of eighth week showed the difference, and it had statistical meaning between both groups （P〈0.05）. SANA effective rate of AnShen capsules group was 79.9%, CGI clinical progress rate was 86.6%; lower than 85.3% and 89.3% of risperdal group, the difference had no statistical meaning （P〉0.05）, A nShen capsules group was lower than risperdal group in adverse reaction incidence. Conclusion： AnShen capsules are effective in improving social and cognitive functions of CS patients.